<DOC>
	<DOCNO>NCT02098174</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics MP-3180 ( 1 µmol/kg ) compare pharmacokinetics iohexol ( 5 mL 300 mg iodine ( I ) /mL solution ) healthy adult participant . The secondary objective evaluate safety tolerability MP-3180 healthy adult participant .</brief_summary>
	<brief_title>Pharmacokinetics MP-3180 Healthy Volunteers</brief_title>
	<detailed_description>Single-dose pharmacokinetics characterize sixteen ( 16 ) healthy , adult male participant Phase 1 , open-label study follow administration single , intravenous 1 µmol/kg dose 2 minute follow 10 mL saline fasting condition . Iohexol ( Omnipaque-300 , 5 mL 300 mg I/mL solution ) also administer 2 minute follow 10 mL saline . The pharmacokinetics MP-3180 iohexol assess statistical comparison pharmacokinetic parameter derive plasma concentration-time curve urine recovery data .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>1 . Age : 22 year age old 2 . Sex : male childbearing potential female 3 . Capable informed consent 4 . Weight restriction : a. least 50 kg ( 110 lb ) men b. least 48 kg ( 106 lb ) woman c. All participant Body Mass Index ( BMI ) less equal 33 great equal 19 5 . All participant judge Principal Investigator Medical SubInvestigator physician normal healthy prestudy medical evaluation perform within 28 day initial dose study medication 1 . Institutionalized participant use 2 . Social habit : a. Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . b. Ingestion vitamin herbal supplement within 7 day prior initial dose study medication . c. Any significant change dietary exercise habit within 48 hour prior initial dose study medication . d. History drug and/or alcohol abuse within past year , unless currently enrol abstinence program . 3 . Use prescription overthecounter ( OTC ) medication within 7 day prior initial dose study medication . 4 . History significant cardiovascular disease , renal , pulmonary , hematologic , endocrine , immunologic , dermatologic , neurologic ( include history seizure disorder ) , psychological , musculoskeletal disease malignancy unless deem clinically significant Principal Investigator Medical SubInvestigator . 5 . Acute illness time either prestudy medical evaluation dosing . 6 . Not within normal limit clinically significant lab test 7 . Any reason , opinion Principal Investigator Medical SubInvestigator , would prevent participant safely participate study . 8 . Donation loss blood plasma : 50 mL 499 mL within 30 day prior initial dose study medication ; 499 mL within 56 day prior initial dose study medication . 9 . Intolerance venipuncture . 10 . Participants receive investigational drug within 30 day prior initial dose study medication . 11 . History allergy hypersensitivity MP3180 iohexol , related product , inactive ingredient . 12 . Any food allergy , intolerance , restriction special diet , opinion Principal Investigator Medical SubInvestigator , could contraindicate participant 's participation study . 13 . History allergy hypersensitivity iodine contain contrast medium drug .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Glomerular Filtration Rate</keyword>
	<keyword>Acute kidney injury</keyword>
</DOC>